Combination therapy

Delve into the world of Combination therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Combination therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms
CompanyDeals

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms

Bio-Link Capital announced the completion of a strategic investment in TYK Medicines (HKG: 2410), a macromolecule innovative drug company focused on the development of next‑generation antibody therapeutics, including bispecific antibodies,…

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Bio-Thera Solutions Receives NMPA Approval for BAT6005 and BAT1308 Combination Therapy Trial

CompanyDrug

RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer

CompanyDrug

Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study

CompanyDeals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

CompanyDrug

Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval

CompanyDrug

MSD Discontinues Vibostolimab and Keytruda Combo Trial in High-Risk Melanoma

CompanyDrug

BMS’s Opdivo/Yervoy Combo Misses PFS Endpoint in Unresectable Stage III NSCLC Trial

CompanyDrug

Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study

Show More